Thesis The recent decline in net income and revenue growth has raised concerns about the company's ability to maintain its competitive edge in a challenging market.
★ Analysts see FY2026 revenue reaching $5.6B — +16.3% growth in a single year.
What Moves the Stock 01 Changes in regulatory approval timelines for new drugs 02 Market share shifts in the generic drug segment 03 Pricing pressures from competitors 04 New product launches 05 Generic pharmaceuticals - 70% 06 Specialty drugs - 20% 07 Contract manufacturing - 10% 08 Increased focus on specialty pharmaceuticals due to demographic shifts 2488 2540 2593 2645 2698 2600 7079.T Daily 2600.00 May '26 Jun '26 Aug '26 Sep '26
My Notes "Management noted, 'We are facing significant pricing pressures that could impact our margins moving forward.'" Moat: WDB coco's competitive advantage is bolstered by its strong regulatory compliance and established distribution channels. value - The company is currently undervalued based on its low Price/Sales and Price/Book ratios. The company's low debt levels (Debt/Equity of 0.02) mean that rising interest rates have minimal direct impact on financing costs… Watch on earnings: Generic drug pricing trends, Regulatory approval rates for new products, Market share in the Japanese pharmaceutical market. One Sentence Summary: WDB coco: the story is balanced — changes in regulatory approval timelines for new drugs.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.
